Drug Information Association Logo

Pharmacovigilance and Risk Management Strategies 2011 Provide Expert Strategies for Developing and Evaluating Safe Use of Marketed Medical Products

Horsham, PA, USA — Dec 14, 2010

DIA will host Pharmacovigilance and Risk Management Strategies 2011 from January 9-12, 2011 in Washington, DC.

This comprehensive three-day program will discuss the current complexities and controversies in pharmacovigilance and risk management throughout all phases of development and marketed use. Sessions will include:

  • Pharmacovigilance and Medical Product Safety: International Perspectives
  • Analysis of Health Care
  • Pharmacovigilance and Medical Product Safety: US Perspectives
  • Early Understanding of Clinical Safety and Risk
  • Drug Safety and Pharmacovigilance Inspections: FDA, European Union, and Japanese Approaches
  • Current Approaches to Pharmacovigilance and Risk Management
  • Safety Consideration When Developing a Proprietary Name

Nancy J. Norton, President, International Foundation for Functional Gastrointestinal Disorders, will deliver the keynote presentation titled, “Impact of Risk Management Programs: Patient Perspective.”

“Clinical trial safety and postmarketing pharmacovigilance is more critical than ever in the development and evaluation of the safe use of marketed medical products,” says Program Co-chair Annette Stemhagen, DrPH, FISPE, Senior Vice President, Safety, Epidemiology, Registries, and Risk Management, United BioSource Corporation. “This conference will explore how to crate and utilize risk management strategies to create an effective organizational ‘system.’”






ABOUT DIA: DIA is the global connector in the life sciences product development process. Our association of more than 18,000 members builds productive relationships by bringing together regulators, innovators and influencers to exchange knowledge and collaborate in an impartial setting. DIA’s network creates unparalleled opportunities for the exchange of knowledge and has the interdisciplinary experience to prepare for future developments. The dedicated efforts of DIA staff, members and speakers enable DIA to provide a comprehensive catalogue of conferences, workshops, training courses, scientific publications and educational materials. DIA is a global community representing thousands of stakeholders working together to bring safe and effective products to patients. DIA is an independent, nonprofit organization with its global center in Washington, D.C., USA; regional offices covering North and South America (Horsham, Penn., USA); Europe, North Africa and the Middle East (Basel, Switzerland); and Japan (Tokyo), India (Mumbai) and China (Beijing). For more information, visit www.diahome.org.